KRAS mutation in advanced lung cancer: Response to Apatinib and clinical outcomes

Lung cancer is a malignant respiratory tumor with rapid development and poor prognosis. VATS(video-assisted thoracic surgery) is the main treatment for early lung cancer, but the majority of patients are diagnosed at stage IIIB or IV. Platinum-based chemotherapy regimen is currently considered key components of first-line chemotherapy for advanced lung cancer; however, there are no standard treatment plans for lung cancer with KRAS mutation. Apatinib has been successfully applied as third-line treatment for advanced gastric cancer and has shown high efficacy in the treatment of various cancer. Herein we report a case of advanced lung cancer harboring KRAS mutation in which apatinib was administered and a partial response was achieved after four months of treatment. To date, a 10 months of progression-free survival have been achieved. Adverse reactions can be controlled and the patient's quality of life has improved. Apatinib provides a new option for clinicians to treat patients with advanced KRAS-mutation lung cancer.

Author(s): Yang Yuan1 and Ma Qianli2

Abstract | PDF

Share This Article
30+ Million Readerbase
Google scholar citation report
Citations : 374

Der Pharmacia Sinica received 374 citations as per google scholar report

Abstracted/Indexed in
  • Google Scholar
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • Proquest Summons
  • International Committee of Medical Journal Editors (ICMJE)
  • Serials Union Catalogue (SUNCAT)
  • Geneva Foundation for Medical Education and Research
  • Secret Search Engine Labs

View More »

Flyer image